Device Trial Radar · NCT07546617
In Vivo Imaging of the Olfactory Epithelium Using Confocal Laser Endomicroscopy
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
Nov 30, 2026
Primary completion
Apr 30, 2027
Study completion Jul 31, 2027
Sponsor
- Lead sponsor
- Dartmouth-Hitchcock Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Center for Advancing Translational Sciences (NCATS)
- First posted
- Apr 23, 2026
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This research is being done to better characterize the part of the nose that helps people smell. Currently, the only ways to study smell loss mostly rely on how people report it, rather than being able to see the underlying structures directly. In this study, the team will use a special microscope (Confocal Laser Endomicroscopy (CLE)), originally developed for brain tissue, to look at the part of the nose that helps to detects smell. The study team hopes to identify the tiny structures in that area and see how they might be different in people who have smell loss compared to those who do not. Participation in the study includes completing a smell test (Sniffin' Sticks Extended test), a cognitive screening test, and two questionnaires.
Conditions
- Endonasal Surgery
- Endoscopic Sinus Surgery
- Olfactory Dysfunction
Interventions
CONVIVO systemDevice
Approximately 2-5 minutes following administration of FNa in situ imaging will be performed by the participating surgeon ensuring proper technique. Prior to entering the surgical field, the probe will be covered in a disposable sterile sheath that is manufactured with quality assurance for this purpose. The probe will gently be held against the tissue interface while imaging occurs. Following image acquisition, a pathologist present in the operating room, will review and capture each image.
Fluorescein injection, USP 10%Drug
Sodium fluorescein will be administered intravenously or topically (applied directly to nasal mucosa) at doses of 5-10 mg/kg (not exceeding 20 mg/kg cumulative). Administration will be performed by the anesthesia team in the operating room.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the feasibility of in vivo CLE imaging of the olfactory cleft and nasal turbinate and determine whether CLE features correlate with validated psychophysical olfactory testing and patient-reported quality-of-life measures.Time frame: On day of Surgery, Day 0
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.